Aspek Farmakokimia Obat Antiinflamasi NonSteroid

Presentasi berjudul: "Aspek Farmakokimia Obat Antiinflamasi NonSteroid"— Transcript presentasi:

1 Aspek Farmakokimia Obat Antiinflamasi NonSteroid
Kuliah Farmakokimia FSTOA semester 6 Fak. Farmasi USB

2

3 Struktur enzim COX Keduanya merupakan dimer yang terikat pada membran mikrosomal 4 domain Domain Dimerization Domain yang terikat Membran Domain katalitik– beda pada struktur Domain peptida Terminal– beda panjang

4

5 Interaksi asam arakhidonat – cox binding site

6

7

8

9

10 Inducible (by cytokines) Unchanged by glucocorticoids
COX-1 enzyme COX-2 enzyme Expression Constitutional Inducible (by cytokines) Unchanged by glucocorticoids Blocked by glucocorticoids Expressed at baseline (in stomach, kidneys, platelets, intestines) Expressed during inflammation (in macrophages, synoviocytes) Kinetics Instantaneous inhibition Time-dependent inhibition Inhibition via hydrogen bonding ?Covalent bonding

11 Inflammatory stimulus
Physiological stimulus clotting, parturition, gastrointestinal and renal protection COX-1 constitutive TXA2 platelet aggregation Prostacyclin endothelium-anticlotting stomach mucosa:  H+,  HCO3-,  mucus PGE2 Kidney: arteriolar dilation; Na+/H2O excretion A. PGF2 parturition Inflammatory stimulus (tissue injury, chronic arthritis) macrophages/other cells Proteases Inflammation, redness, swelling, pain B. COX-2 induced by cytokines (e.g., TNF) Other inflammatory mediators (histamine, etc) Prostaglandins especially PGE2 Figure 8. Actions of two known isoforms of cyclooxygenase (COX).

12

13 Classification 1. Non-steroidal Anti-inflammatory Agents
1.1 Non-selective COX-1 Inhibitors 1.2 Selective COX-2 Inhibitors 2. Antipyretic Analgesics

14 1. Anti-inflammatory Agents
1.1 Non-selective Cycloxygenase (COX) -1 Inhibitors 1.1.1 Salicylates 1.1.2 Arylalkanoic Acids Aryl- and Heteroarylacetic Acids Aryl- and Heteroarylpropionic Acids 1.1.3 N-Arylanthranilic Acids (Fenamic Acids) 1.1.4 Oxicams 1.1.5 Phenylpyrazolones 1.2 Selective COX-2 Inhibitors

15 General Structure of NSAIDs
Acidic functional group –COOH; Membentuk ionic bond dengan arginine residue (120) dari COX Aromatic ring / heteroaromatic ring (Acidic functional group); hydrophobic interaction (van der waal force )dengan flat area enzim COX lipophilic part / alkyl chain pada aromatic ring hydrophobic interaction melalui van der waal force

16 Interaksi Indomethacin - COX
CARBOXYL OR ACIDIC GROUP CATIONIC SITE (ARG 120) NH3+ ARYL OR HETERORYL GROUP FLAT AREA ARYL OR ALKYL GROUP LYPOPHILIC GROUP INDOMETHACIN ARACHIDONIC ACID

17 Physicochemical and Pharmacokinetic Properties of NSAIDs
Strong organic acid; pKa ~ 3-5 physiological pH (~7.4) plasma protein binding (~90-99%) karena ionic bond  drug interaction albumin-NSAIDs plasma protein binding carboxylic group (-COOH) mengalami metabolize glucuronide conjugation (phase II)

18 Glucuronide Conjugation
Drugs (NSAIDs) UDP-Glucuronosyl Transferase (UGT) + UDP Acyl-glucuronide metabolite

19 1.1.1 Salicylic acid

20 Salicylate Salts

21 Aspirin or Acetylsalicylic Acid
Tambahan acyl group pada molekul salicylic acid

22 Mechanism of action of Aspirin
Serine residue acetylation COX-1 (Ser 530), COX-2 (Ser 516) or Circulating protein Irreverseble COX inhibition

23 Aspirin and Salicylates
Metabolism of Aspirin and Salicylates Glycine Conjugation Glucuronide GENTISIC ACID SALICYLURIC ACID Aromatic hydroxylation Plasma esterase

24 Salicylamide

25 Salsalate Dimer Salicylic acid
Dihidrolisis menjadi 2 molekul salicylate Efek samping GI bleeding

26 Diflunisal phenyl group (or aromatic ring) pada molekul salicylic acid
Efek samping : GI disturbance, dermatologic reaction , CNS side effect (dizziness and headache)

27 1.1.2 Arylalkanoic Acids 1.1.2.1 Aryl- and Heteroarylacetic Acids
Aryl and Heteroarylpropionic Acids (“-profen”)

28 SAR 1-C ATOM ACIDITY , ACTIVITY  ALKYL GROUP CARBOXYL GROUP ARYL OR
HETERO ARYL GROUP ARYL OR ALKYL GROUP

29 1.1.2.1 Aryl- and Heteroarylacetic Acids
Indomethacin Sulindac Tolmetin (Sodium) Diclofenac (Sodium) Etodolac Nabumetone

30 Indomethacin Indole ring P-Chlorobenzoyl

31 Metabolism of Indomethacin
Serotonin (5HT)

32 Sulindac INDENE LIPOPHILIC BENZYLIDENE SULFINYL GROUP  SOLUBILITY

33 Metabolism of Sulindac
reduction ACTIVE SULFIDE METABOLITE

34 Tolmetin (Sodium) PYROLE RING

35 Metabolism of Tolmetin
Glucuronide conjugation

36 Diclofenac (Sodium)

37 Nabumetone Nabumetone (pro-drug) oxidation naproxen 6-MNA (38%)
NAPHTHALENE naproxen oxidation Nabumetone (pro-drug) 6-MNA (38%) (active metabolite)

38 1.1.2.2 Aryl- and Heteroarylpropionic Acids
Ibuprofen Fenoprofen (Calcium) Ketoprofen Naproxen Flurbiprofen Ketorolac (Tromethamine) Oxaprozin

39 Isomerization R-ENANTIOMER S-ENANTIOMER

40 IBUPROFEN FLURBIPROFEN NAPROXEN CARPROFEN CARBAZOLE NAPHTHALENE
ISOBUTYL GROUP NAPROXEN CARPROFEN CARBAZOLE NAPHTHALENE

41 FENOPROFEN KETOPROFEN KETONE PHENOLIC GROUP OXAPROZIN

42 1.1.3 N-Arylanthranilic Acids (Fenamic Acids)
Salicylic acid Anthranilic acid Bioisosteric group ของ -OH Turunan Anthranilic acid merupakan modifikasi salicylic acid dengan bioisosteric replacement

43 Anthranilic Acid (Fenamic Acid)
Anthranilic acid ring N-aryl ring Mefenamic Acid Meclofenamate (Sodium)

44 SAR OXICAM R : aryl atau heteroaryl sybstituent R1–CH3 untuk
Enolic group; pKa ~ 4-6 R : aryl atau heteroaryl sybstituent R1–CH3 untuk optimum activity 4-hydroxy-1,2-benxothiazine carboxamides

45 2-(5-methtyl)thiazolyl group
2-pyridyl group 2-(5-methtyl)thiazolyl group Primary carboxamide Primary carboxamide Meloxicam Piroxicam

46 Stabilization of Enolate Anion
H+

47 Piroxicam

48 Meloxicam selective cox-2 inhibitor (by FDA approving)

49 Selective COX-2 Inhibitors
Celecoxib Rofecoxib

50 Valdecoxib Parecoxib (IM) (pro-drug of Valdecoxib) Parecoxib Sodium (IV)

51 COX-1 and COX-2

52 Flurbiprofen; Non-Selective COX inhibitors

53 Interaksi dengan COX-1 & COX-2 : Non-selective COX inhibitor

54 Celecoxib;Selective COX-2 inhibitors

55 Interaksi dengan COX-1 & COX-2 : Selective COX-2 inhibitor

56 antipyretic analgesics
Acetaminophenol Phenacetin Acetanilide

57 Metabolism and Toxicity
MINOR MAJOR MAJOR MINOR METHEMOGLOBINEMIA METHEMOGLOBINEMIA HEMOLYTIC ANEMIA HEMOLYTIC ANEMIA

58 Metabolism and Toxicity
-H2O MINOR N-ACETYLIMIDOQUINONE TOXIC METABOLITE GSH HEPATIC OR RENAL PROTEIN MAJOR SULFATE OR GLUCURONIDE CONJUGATION HEPATIC NECROSIS AND RENAL FAILURE Excreted form

59 Metabolic Intoxicification
GLUTATHIONE DETOXIFIES URINARY METABOLITE N-ACETYLCYSTEINE

60

61

62 Boundary surface defining the cyclooxygenase binding pocket computed on the COX-1 isozyme with GRID. Different regions of the pocket as well as the side chains of key residues are explicitly shown.

63 Superposition of the optimized structures of ketoprofen bound according to model 2 to each of the two isozymes. Docking onto COX-1 is shown in yellow, and onto COX-2 in magenta. The inner surface of the binding pocket is shown in blue.

64  Structure of rofecoxib (in magenta) and ketoprofen (in yellow) docked into the binding site of COX-2, whose inner surface is shown in blue.

65 Inhibitor Selektif COX -2
Penghambatan COX-2 : efek anti-inflamasi Penghambatan COX-1 : toksisitas NSAID, a) peptic ulcer dan resiko perdarahan, b) memperlama bleeding time; c) renal insufficiency . Ditargetkan pada jaringan yg radang, tapa mengganggu fungsi homeostatic prostaglandin di organ yg tidak radang. Secara teroritis, inhibitor selektifCOX-2 masih akan memberikan efek anti-inflamasi

66 COX inhibitors Non Selective COX inhibitors
Non competitive Aspirin Competitive Phenylbutazone Ibuprofen Naproxen Diclofenac Piroxicam Ketorolac Analgesic with Antipyretic without anti inflammatory action Paracetamol Metamizol Nefopam Preferential COX – 2 inhibitors Nimesulide Meloxicam Nabumetone Selective COX -2 inhibitors Celcoxib Rofecoxib Valdecoxib Etoricoxib Parecoxib Lumoracoxib

67 Golongan inhibitor selektif COX-2
turunan karbosiklis dan Heterosiklis yang terikat visinal dengan moieties aril (Ex. Celexocib, rofexocib), turunan diaril- atau aril/heteroaril-eter dan –tioeter, turunan cis-stilben, keton diaril dan aril/heteroaril.

68

69 Selektivitas Ratio aktivitas penghambatan COX–1 / COX–2
Aktivitas COX-1 : kemampuan untuk menghambat produksi TXB 2 dari platelets Aktivitas COX–2 : kemampuan penghambatan produksi PGI 2 dari monosit sebagai respon stimuli

70

71 Inhibitor selektif COX-2
Pada penanganan pasien-pasien osteo- dan rheumatoidarthritis, inhibitor selektif COX-2 menunjukkan kerja antiradang yang setara dengan obat antiradang bukan steroid klasik tetapi dengan toksisitas lebih ringan pada saluran gastrointestinal. Namun demikian, dilaporkan pula adanya kecendrungan peningkatan tekanan darah sebagai efek samping inhibitor selektif COX-2

72 Inhibitor selektif COX-2
Muncul pertanyaan, apakah inhibitor selektif COX-2 benar-benar toksisitasnya lebih ringan sehingga lebih aman digunakan atau bahkan memiliki efek merugikan lain yang berbeda dari efek merugikan yang disebabkan oleh obat anti radang bukan steroid klasik?